MARKET

PEN

PEN

Penumbra Inc
NYSE
201.84
-6.84
-3.28%
After Hours: 201.84 0 0.00% 16:20 04/18 EDT
OPEN
208.15
PREV CLOSE
208.68
HIGH
208.60
LOW
200.96
VOLUME
330.45K
TURNOVER
0
52 WEEK HIGH
348.67
52 WEEK LOW
180.93
MARKET CAP
7.81B
P/E (TTM)
87.03
1D
5D
1M
3M
1Y
5Y
Penumbra Becomes Oversold (PEN)
NASDAQ · 1h ago
3 Best Stocks to Buy Now, 4/16/2024, According to Top Analysts 
TipRanks · 2d ago
Weekly Report: what happened at PEN last week (0408-0412)?
Weekly Report · 3d ago
Piper Sandler Remains a Buy on Penumbra (PEN)
TipRanks · 6d ago
Penumbra, Inc.'s (NYSE:PEN) Earnings Haven't Escaped The Attention Of Investors
Penumbra, Inc.'s price-to-sales ratio of 8.1x is high compared to the Medical Equipment industry in the U.S. The company grew revenue by 25% last year and is expected to grow by 17% per year over the next three years. Penumbra's P/S ratio is high on the merit of its strong future revenues.
Simply Wall St · 6d ago
A Leaner AngioDynamics Is A High-Risk Execution-Driven Story
AngioDynamics has sold low-growth businesses, shifted to an outsourced manufacturing model, and refocused on cardiovascular and oncological care for potential growth. Recent approval of the AlphaVac F18 mechanical thrombectomy system for pulmonary embolism presents a significant opportunity in a growing market. The company's historical execution challenges raise concerns, but there is potential for a stronger, more profitable Angiodynamics.
Seeking Alpha · 04/09 20:49
Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024
Penumbra, Inc. Will host a conference call to discuss financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024. The conference call can be accessed live over the phone or on the company's website. A press release will be issued with financial results.
PR Newswire · 04/09 20:05
Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse'
Jim Cramer said he prefers Abbott Laboratories over Penumbra. The "Mad Money" host said Emerson Electric Co. Is now working. Ford Motor Company is doing well and the company's stock is starting to come back, he said. Cramer was on CNBC's 'Mad Money Lightning Round'
Benzinga · 04/09 13:10
More
About PEN
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.

Webull offers Penumbra Inc stock information, including NYSE: PEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PEN stock methods without spending real money on the virtual paper trading platform.